Locally Advanced or Metastatic NSCLC Clinical Trial
Official title:
Phase I Trial of PBF-1129 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase I clinical trial in Eastern Cooperative Oncology Group (ECOG) 0-1 patients with locally advanced or metastatic NSCLC to evaluate safety and tolerability of the compound PBF-1129, an Adenosine A2b receptor antagonist. The phase I dose escalation will be conducted 3+3 method. Pharmacokinetic (PK) data will be also obtained.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03037086 -
Asia PDL1 Study Among NSCLC Patients
|
N/A | |
| Recruiting |
NCT05662670 -
A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03502850 -
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05990127 -
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03969823 -
Whole Genomic Landscape of Advanced EGFR-mutant NSCLC
|
N/A | |
| Completed |
NCT04207775 -
Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
|
||
| Completed |
NCT05631678 -
Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole
|
Phase 1 | |
| Recruiting |
NCT04143607 -
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
| Completed |
NCT03414814 -
Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation
|
Phase 2 | |
| Completed |
NCT04360915 -
Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects
|
Phase 1 |